NCT06400303View on ClinicalTrials.gov

KYSA-5: A Study of Anti-CD19 Chimeric Antigen Receptor T-Cell (CD19 CAR T) Therapy, in Subjects With Systemic Sclerosis

PHASE1/PHASE2Active, not recruitingINTERVENTIONAL
Enrollment

3

Participants

Timeline

Start Date

August 6, 2024

Primary Completion Date

March 31, 2026

Study Completion Date

March 31, 2027

Conditions
Systemic SclerosisSystemic Sclerosis - Diffuse CutaneousSystemic Sclerosis - 2013 ACR/EULAR Classification Criteria
Interventions
BIOLOGICAL

KYV-101

Anti-CD19 CAR-T cell therapy

DRUG

Standard lymphodepletion regimen

Standard lymphodepletion regimen

Trial Locations (2)

11021

Northwell Health, Great Neck

94305

Stanford University Medical Center, Palo Alto

Sponsors
All Listed Sponsors
lead

Kyverna Therapeutics

INDUSTRY

NCT06400303 - KYSA-5: A Study of Anti-CD19 Chimeric Antigen Receptor T-Cell (CD19 CAR T) Therapy, in Subjects With Systemic Sclerosis | Biotech Hunter | Biotech Hunter